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Abstract.
Background: GNE myopathy is a rare, autosomal recessive, muscle disease caused by mutations in GNE and is characterized
by rimmed vacuoles on muscle biopsy and progressive distal to proximal muscle weakness.
Objective: Investigate the clinical presentation and progression of GNE myopathy.
Methods: The GNE Myopathy Disease Monitoring Program was an international, prospective, observational study in sub-
jects with GNE myopathy. Muscle strength was assessed with hand-held dynamometry (HHD), with upper extremity (UE)
and lower extremity (LE) composite scores reflecting upper and lower extremity muscle groups, respectively. The GNE
myopathy–Functional Activity Scale (GNEM-FAS) was used to further assess impairment in mobility, upper extremity
function, and self-care.
Results: Eighty-seven of 101 enrolled subjects completed the trial until study closure by the sponsor; 60 completed 36
months. Mean (SD) HHD UE composite score decreased from 34.3 kg (32.0) at baseline to 29.4 kg (32.6) kg at month 36
(LS mean change [95% CI]: –3.8 kg [–5.9, –1.7]; P = 0.0005). Mean (SD) HHD LE composite score decreased from 32.0 kg
(34.1) at baseline to 25.5 kg (31.2) at month 36 (LS mean change [95% CI]: –4.9 [–7.7, –2.2]; P = 0.0005). GNEM-FAS
scores were more severe at baseline in subjects who walked <200 meters versus ≥200 meters in 6 minutes; in both groups,
GNEM-FAS total, mobility, UE, and self-care scores decreased from baseline through month 36.
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Conclusions: These findings demonstrate progressive decline in muscle strength in GNE myopathy and provide insight into
the appropriate tools to detect clinically meaningful changes in future GNE myopathy interventional trials.
Keywords: Myopathies, muscular diseases, muscle weakness, N-acetylneuraminic acid
INTRODUCTION
GNE myopathy (also known as hereditary
inclusion body myopathy, Nonaka Distal Myopa-
thy or Rimmed Vacuole Myopathy) is a rare,
autosomal recessive, muscle disease caused by
mutations in GNE, the gene coding for the bifunc-
tional UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase [1–3]. This enzyme is
the first step in the biosynthesis of sialic acid (SA)
required for the glycosylation of proteins and lipids.
GNE myopathy is characterized by rimmed vacuoles
on a muscle biopsy and usually presents with often
severe muscle weakness that slowly progresses dis-
tally to proximally, eventually compromising arm and
leg muscle function, but sparing the quadriceps mus-
cles. Wheelchair use may be required in 10 to 20
years after symptom onset. The prevalence of GNE
myopathy is estimated at 1 to 9/1,000,000 [2]. While
there are currently no approved treatments for GNE
myopathy, increasing SA in a GNE myopathy mouse
model with oral supplementation reduced muscle
weakness and pathology [4]; proof-of-concept gene
therapy research has also shown promise in mice [5].
Two previous studies have provided insight into
the natural history of GNE myopathy [6, 7]. Mori-
Yoshimura et al, 2014 followed 24 Japanese patients
with GNE myopathy for one year noting declines in
pulmonary function and muscle testing, including the
6-minute Walk Test and grip power. In an effort to
understand disease progression over a longer period
of time, Quintana et al, 2019 developed a Bayesian
model of GNE myopathy based upon natural his-
tory data from 38 subjects followed for an average of
14 months that showed declines in muscle strength
and physical functioning as a function of estimated
disease progression.
As a part of a larger clinical program investigat-
ing the safety and efficacy of an extended—release
formulation of aceneuramic acid as supplementation
therapy for GNE myopathy, Ultragenyx Pharmaceu-
tical Inc. developed a Disease Monitoring Program
(GNEM-DMP; Study UX001-CL401). The GNEM-
DMP comprises two non-interventional studies: an
online survey, which was reported previously [8], and
an in-clinic study. This report describes the results of
the in-clinic component of the GNEM-DNP in 101
subjects with GNE myopathy followed for 3 years.
MATERIALS AND METHODS
Study design
The GNEM-DMP was an international, non-
interventional, observational study to better under-
stand the presentation, progression, geographic
distribution, and prevalence of GNE myopathy. Add-
itionally, the study aimed to provide connection for
subjects to the broader GNE myopathy community
and share the clinical outcomes of this study in
an effort to further develop potential GNE thera-
pies. The GNEM-DMP was comprised of an online,
patient- or caregiver—reported component and an in-
clinic, physician—reported component, and subjects
were allowed to participate in either or both com-
ponents of the program. This report summarizes the
in-clinic component of the study; the online compo-
nent was previously published [8]. After completing
a consent form, subjects were assessed at baseline,
6 months ( ± 1 month), 12 months, 24 months, and
36 months ( ± 3 month). In-clinic visits lasted a full
day and assessed medical history or interval history
for subsequent visits, prior and concomitant medi-
cations, muscle strength, patient-reported outcomes,
and safety.
The institutional review board at each participating
center approved the protocol. The study was con-
ducted in accordance with the Declaration of Helsinki
and the Good Clinical Practice guidelines developed
by the International Conference on Harmonization of
Technical Requirements for Registration of Pharma-
ceuticals for Human Use. This study is registered on
ClinicalTrials.gov (NCT01784679).
Subjects and assessments
Key inclusion criteria included age ≥18 years,
willingness to release access to medical informa-
tion for the study, and diagnosis of GNE myopathy
(genetic confirmation was not required for the online
component, but was required for the in-clinic compo-
nent). Subjects with an unrelated, comorbid disease
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or condition that may have interfered with study par-
ticipation or affected safety, in the opinion of the
investigator, were excluded from participation.
The following were assessed by hand-held
dynamometry (HHD) or manual muscle testing
(MMT) using a microFET®2 or Jamar hydraulic hand
dynamometer: gross grip, pinch, shoulder abduc-
tors, elbow flexors, elbow extensors, hip flexors, hip
extensors, hip abductors, hip adductors, knee flex-
ors, and knee extensors. Composite HHD scores were
calculated for the sum of the upper (grip, shoul-
der abductors, elbow flexors, and elbow extensors)
and lower (hip flexors, hip extensors, hip abduc-
tors, hip adductors, and knee flexors) muscle groups.
Ambulatory subjects completed the 6-minute Walk
Test (6MWT) and Stair Climb Test. All subjects
completed the pulmonary function test. The GNE
myopathy - Functional Activity Scale (GNEM-FAS),
assessed in both ambulatory and non-ambulatory
subjects, is a validated instrument with qualita-
tive and quantitative measures designed to assess
functional impairment in GNE myopathy including
mobility, upper extremity (UE) function, and self-
care; higher GNEM-FAS scores indicate a lower level
of impairment [9, 10]. The incidence and severity
of adverse events (AEs) were collected to assess
safety. Additional assessments are listed in the study
protocol available at ClinicalTrials.gov (identifier:
NCT01784679) and clinicaldata.ema.europa.eu (pro-
cedure number: EMEA/H/C/004176/0000).
Statistical analysis
For continuous variables, the data were described
using descriptive summaries such as median, mean,
standard deviation, standard error of the mean,
and range. For categorical variables, descriptive
summaries include counts and proportions. For
repeated measures, least squares (LS) mean change
from baseline and 95% confidence intervals (CI)
were calculated using the generalized estimat-
ing equation (GEE) model. Subjects receiving
N-acetyl-D-mannosamine (ManNAc) and/or intra-
venous immune globulin (IVIG) at baseline were
excluded from the analysis. As described above, some
assessments were only feasible in ambulatory sub-
jects, and therefore, only analyzed in ambulatory
subjects. A ad hoc analysis examining clinical end-
points in Bulgarian subjects, accounting for nearly
half of all participants (47/101) in the study, was con-
ducted to evaluate potential differences in a subgroup
with a homogenous mutation. Bulgaria is home to a
cluster of patients with GNE myopathy thought to
express the same founder mutation [11, 12].
Individual de-identified participant data will be
available for 12 months from the time of pub-
lication upon request to researchers providing a
methodologically sound proposal for analysis for
research that contributes to the field of GNE
myopathy. Proposals should be directed to clinical-
datarequest@ultragenyx.com. To gain access, data
requestors will need to sign a data access and use
agreement. Data will be shared via a secure portal.
RESULTS
Baseline characteristics
Between April 5, 2013, and January 11, 2018,
101 subjects were enrolled in the study, 87 (86.1%)
of whom completed the study up to the point of
early closure by the sponsor on January 11, 2018.
The remaining 14 subjects discontinued due to death
(n = 3), consent withdrawn (n = 2), principal investi-
gator decision (n = 2), non-compliance (n = 1), other
(n = 1), and no reason given (n = 5). Ninety-eight
subjects (97%) completed 6 months, 92 (91%) com-
pleted 12 months, 81 (80%) completed 24 months,
60 (59%) completed 36 months, and 9 (9%) com-
pleted 48 months. Six subjects who were receiving
ManNAc and/or IVIG were excluded from this anal-
ysis. Because so few subjects completed 48 months
due to early study closure, data is reported through
month 36.
The majority of enrolled (N = 101) subjects were
male, white, and Roma (Table 1). Forty-seven sub-
jects (47%) reported a misdiagnosis, 56 (55%)
reported their first GNE myopathy symptom as
“tripping/foot-drop/toe-drop,” and 16 (16%) reported
“walking funny/unsteady gait/difficulty walking.”
At baseline, 40 subjects (40%) were using lower
extremity (LE) orthotics, 27 (27%) were using an
assistive walking device, and 39 (39%) were using
a wheelchair/scooter. Approximately one-half of the
subjects (n = 48; 48%) reported previous use of med-
ications specifically for GNE myopathy (or HIBM),
including SA, ManNAc, IVIG, sialyllactose, St.
John’s Wort, and creatine. At enrollment, the most
frequent medications for GNE myopathy were SA
(n = 39; 39%) and creatine (n = 17; 17%), and the
most frequent non—medications for GNE myopa-
thy were physical therapy (n = 48; 48%) and massage
(n = 16; 16%). Concomitant use of creatine was
reported for 7 of 76 (9%) subjects at month 24 and 4
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Table 1
Baseline Demographics and Characteristics
Demographic or Characteristic All Subjects
(N = 101)
Male, n (%) 55 (54.5)
Age, years, mean (SD) 39.2 (12.2)
Height, (cm), mean (SD) 168.9 (9.7)
Weight, (kg), mean (SD) 73.8 (16.8)
Race, n (%)
White (Hispanic/Latino) 2 (2.0)
White (Non-Hispanic/Latino) 87 (86.1)




Persian Jewish descent 3 (3.0)





6MWT Category, n (%)
Able to Complete ≥200 Meters 46 (45.5)
Completed <200 Meters or Unable to Complete Test 55 (54.5)
Age at First Symptom, years, mean (SD) 26.0 (8.5)
Age at GNE Myopathy Diagnosis, years, mean (SD) 33.7 (10.8)
Medical History and Symptoms, n (%)
Tripping/foot-drop/toe-drop 91 (90.1)
Walking funny/unsteady gait/difficulty walking 86 (85.1)
Frequent falls 58 (57.4)
Weakness in legs/feet 84 (83.2)
Weakness in arms/hands 74 (73.3)
Fatigue 48 (47.5)
Muscle twitching/spasms 16 (15.8)
Muscle pain 39 (38.6)
Difficulty climbing stairs 83 (82.2)
Difficulty moving and changing positions 56 (55.4)
Othera 18 (17.8)
Creatine kinase, U/L, mean (SD)b 414.1 (439.5)
Free Sialic Acid Level, g/mL, mean (SD)b 0.17 (0.08)
HHD Upper Extremity Composite Score, kg, mean (SD)b 34.3 (32.0)
HHD Lower Extremity Composite Score, kg, mean (SD) b 32.0 (34.1)
aIncludes British (n = 10), Scottish (n = 4), Non-Persian Jewish (n = 3), Dutch (n = 2), Algerian
(n = 1), Canadian (n = 1), French and British (n = 1), French and UK (n = 1), Irish (n = 1), Irish and
Norwegian (n = 1), Jewish Karaite (n = 1), Scottish (n = 4), Senegalese (n = 1), South American
(n = 1), Spanish (n = 1), UK (n = 1), and Unknown (n = 1). bExcludes 6 subjects who were taking
ManNAc and/or IVIG at baseline. 6MWT, 6-minute Walk Test; HHD, hand held dynamometry.
of 58 (7%) subjects at month 36. No concomitant use
of SA was reported at months 24 and 36.
Hand held dynamometry upper extremity and
lower extremity composite scores
Mean HHD UE composite scores decreased from
baseline through month 36, with a decreased LS mean
change from baseline to month 36 of –3.8 kg (95%
CI: –5.9, –1.7; P = 0.0005; Fig. 1A, Supplemental
Table 1). Mean HHD LE composite scores decreased
from baseline through month 36, with a decreased LS
mean change from baseline to month 36 of –4.9 kg
(95% CI: –7.7, –2.2; P = 0.0005; Fig. 1B, Supplemen-
tal Table 1). Mean raw strength scores for individual
muscle groups included in the HHD UE and LE
composites likewise declined, with at least one sta-
tistically significant LS mean change from baseline
all individual muscle groups (Table 2).
In an ad hoc subgroup analysis, mean HHD UE and
LE scores were more severe at baseline and through-
out the study in 47 Bulgarian subjects compared with
46 non-Bulgarian subjects who had baseline and post-
baseline data (Supplemental Table 2). The mean (SD)
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Fig. 1. Mean ± SE change from baseline to month 36 in hand-
held dynamometry upper extremity and lower extremity composite
scores. Subject numbers are shown above the x-axis. ∗∗P<0.01,
∗∗P<0.001, and ∗∗∗P<0.0001 using the GEE model. GEE, gener-
alized estimating equation; LS, least squares; SE, standard error.
age of first GNEM symptom was earlier in Bulgar-
ian subjects compared with non-Bulgarian subjects
(23.7 [6.4] vs 28.0 [9.6] years), as was mean (SD)
age of GNEM diagnosis (31.0 [9.0] vs 36.1 [11.8]
years). Mean HHD UE composite scores decreased
from baseline through month 36 in Bulgarian and
non-Bulgarian subjects, with a decreased in LS mean
change from baseline to month 36 in Bulgarian sub-
jects of –2.9 kg (95% CI: –5.2, –0.6; P = 0.0145)
and –5.1 kg (95% CI, –8.8, –1.3; P = 0.0085) in
non-Bulgarian subjects (Fig. 2A). Similarly, mean
HHD LE composite scores decreased from baseline
through month 36 in Bulgarian and non-Bulgarian
subjects, with a decrease in LS mean change from
baseline to month 36 in Bulgarian subjects of –1.5 kg
(95% CI: –3.4, –0.3; P = 0.1028) and –8.8 kg (95%
CI: –14.0, –3.6; P = 0.0009) in non-Bulgarian sub-
jects (Fig. 2B).
GNE myopathy – functional activity scale
As expected, GNEM-FAS scores (total, mobil-
ity, UE, and self-care) were more severe at baseline
and throughout the study in subjects who walked
<200 meters in baseline 6MWT (ie, “<200-meter
subjects”) than in subjects who walked ≥200 meters
(ie, “≥200-meter subjects”) (Supplemental Table 1).
Mean GNEM-FAS total scores decreased from base-
line through month 36, with a decrease in LS mean
for from baseline to month 36 in ≥200-meter sub-
jects of –6.3 units (95% CI: –9.4, –3.2; P<0.0001)
and –12.3 units (95% CI: –18.3, –6.3; P<0.0001) in
<200-meter subjects (Fig. 3A).
Among the GNEM-FAS subscores, mean GNEM
FAS mobility scores decreased from baseline through
month 36, with a decrease in LS mean change
from baseline to month 36 for ≥200-meter sub-
jects of –2.8 units (95% CI: –4.5, –1.2; P = 0.0007)
and –5.7 units (95% CI: –8.9, –2.5; P = 0.0005) in
<200-meter subjects (Fig. 3B). Mean GNEM-FAS
UE scores decreased from baseline through month
36, with a decrease in LS mean change from base-
line to month 36 in ≥200-meter subjects of –1.8
units (95% CI: –2.9, –0.7; P = 0.0009) and –3.1
units (95% CI: –5.1, –1.0; P = 0.0033) in in <200-
meter subjects (Fig. 3C). Mean GNEM-FAS self-care
scores decreased from baseline through month 36,
with a decrease in LS mean change from baseline
to month 36 in ≥200-meter subjects of –1.6 units
(95% CI: –2.6, –0.6; P = 0.0015) and –3.7 units (95%
CI: –5.6, –1.7; P = 0.0003) in <200-meter subjects
(Fig. 3D).
In the ad hoc subgroup analysis, mean GNEM-
FAS total scores in ≥200-meter Bulgarian subjects
decreased from baseline through month 36, with a
decrease in LS mean change from baseline to month
36 of –2.0 units (95% CI: –5.9, 1.9; P = 0.3134;
Fig. 4).
Six-minute walk test
For all subjects, the mean distance walked in
the 6MWT and the percentage of predicted dis-
tance walked in the 6MWT increased from baseline
through month 36 (Supplemental Table 1). However,
variability was high among ≥200-meter subjects
and < 200-meter subjects, and no statistically signif-
icant LS mean changes from baseline were observed
at any time point (Fig. 5).
Additional clinical outcomes
Pulmonary function assessments were added to the
study protocol after the study was initiated. There-
fore, only three subjects were evaluated at baseline
for forced vital capacity, with a mean (SD) of 3.1 L
(0.3). Over time, there was little change in this score,
with a mean (SD) of 3.0 L (0.7) in six subjects at



















Change in Individual Muscle Groups with Hand-Held Dynamometry
Muscle Groups All Subjects
Baseline Month 6 Month 12 Month 24 Month 36
Gross Grip, kg
Mean (SD) [n] 12.6 (13.7) [95] 12.8 (14.0) [92] 12.6 (14.2) [90] 11.9 (14.0) [76] 10.8 (13.9) [67]
LSM (95% CI) change from baseline — 0.01 (–0.5, 0.5) –0.4 (–0.9, 0.2) –0.7 (–1.4, 0.1) –1.3 (–2.1, –0.4)
P value — 0.9532 0.1627 0.0949 0.0051
Shoulder Abductors, kg
Mean (SD) [n] 7.8 (7.3) [93] 7.8 (7.3) [89] 7.7 (7.3) [87] 6.3 (6.5) [74] 5.6 (5.8) [61]
LSM (95% CI) Change from Baseline — –0.2 (–0.6, 0.3) –0.4 (–0.8, 0.1) –1.2 (–1.6, –0.8) –1.3 (–1.9, –0.8)
P value — 0.4661 0.0920 <0.0001 <0.0001
Elbow Flexors, kg
Mean (SD) [n] 7.9 (7.7) [95] 7.7 (8.1) [88] 7.5 (8.0) [86] 6.8 (7.3) [74] 7.1 (7.8) [57]
LSM (95% CI) Change from Baseline — –0.2 (–0.6, 0.2) –0.5 (–0.9, –0.1) –0.8 (–1.3, –0.3) –0.9 (–1.6, –0.2)
P value — 0.3847 0.0181 0.0015 0.0082
Elbow Extensors, kg
Mean (SD) [n] 6.1 (5.6) [94] 5.9 (5.6) [88] 5.9 (5.7) [86] 5.6 (5.4) [74] 5.6 (5.5) [57]
LSM (95% CI) Change from Baseline — –0.2 (–0.5, 0.04) –0.3 (–0.6, –0.1) –0.5 (–0.9, –0.1) –0.6 (–1.0, –0.2)
P value — 0.0928 0.0029 0.0077 0.0089
Hip Abductors, kg
Mean (SD) [n] 10.2 (7.9) [95] 9.5 (7.7) [89] 9.9 (8.2) [86] 9.3 (8.4) [75] 9.4 (8.7) [58]
LSM (95% CI) Change from Baseline — –0.7 (–1.2, –0.2) –0.5 (–1.0, 0.1) –0.7 (–1.4, –0.009) –0.8 (–1.5, 0.02)
P value — 0.0049 0.0880 0.0472 0.0559
Hip Adductors, kg
Mean (SD) [n] 4.3 (6.2) [94] 3.9 (5.7) [87] 4.0 (5.8) [85] 3.5 (6.0) [74] 4.0 (7.0) [58]
LSM (95% CI) Change from Baseline — –0.1 (–0.4, 0.2) –0.4 (–0.8, 0.1) –0.6 (–1.1, –0.1) –0.4 (–1.2, 0.4)
P value — 0.5106 0.1078 0.0163 0.2969
Hip Flexors, kg
Mean (SD) [n] 4.9 (7.9) [93] 5.0 (8.3) [88] 4.5 (7.3) [86] 3.5 (6.4) [73] 3.3 (5.8) [52]
LSM (95% CI) Change from Baseline — 0.1 (–0.4, 0.5) –0.5 (–0.9, –0.1) –1.0 (–1.5, –0.5) –1.3 (–1.9, –0.6)
P value — 0.7232 0.0148 0.0001 0.0001
Hip Extensors, kg
Mean (SD) [n] 8.6 (9.3) [88] 8.5 (9.7) [84] 8.2 (9.8) [82] 7.0 (9.4) [72] 6.1 (8.0) [51]
LSM (95% CI) Change from Baseline — –0.04 (–0.8, 0.7) –0.5 (–1.3, 0.4) –1.3 (–2.4, –0.3) –2.1 (–3.3, –1.0)
P value — 0.9140 0.2711 0.0154 0.0002
Knee Flexors, kg
Mean (SD) [n] 3.8 (5.8) [93] 4.0 (7.0) [88] 3.7 (6.3) [85] 3.0 (5.8) [75] 2.8 (5.4) [59]
LSM (95% CI) Change from Baseline — –0.1 (–0.4, 0.3) –0.1 (–0.5, 0.2) –0.7 (–1.1, –0.3) –1.0 (–1.4, –0.5)
P value — 0.7125 0.4873 0.0019 <0.0001
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Fig. 2. Mean ± SE change from baseline to month 36 in hand-
held dynamometry upper extremity and lower extremity composite
scores in Bulgarian and non-Bulgarian subjects. Subject numbers
are shown above the x-axis. ∗P<0.05, ∗∗P<0.01, and ∗∗∗P<0.001
using the GEE model. GEE, generalized estimating equation; LS,
least squares; SE, standard error.
Fig. 4. Mean ± SE change from baseline to month 36 in GNEM-
FAS total score in Bulgarian subjects. Subject numbers are shown
above the x-axis. ∗P<0.05 using the GEE model. GEE, generalized
estimating equation; LS, least squares; SE, standard error.
L (1.0) in 19 subjects at month 24, and 3.5 L (0.9) in
22 subjects at month 36.
Most subjects (∼90%) who remained in the study
through month 36 continued to report new GNE
myopathy symptoms, complications, or conditions
following their baseline visit (Supplemental Table 3).
Excluding the six subjects receiving ManNAc or
IVIG at baseline, mean (SD) free SA was 0.2 g/mL
(0.1) at baseline and at months 12, 24, and 36. Mean
(SD) serum creatine kinase was 414 U/L (439) at
baseline, 380 U/L (393) at month 12, 292 U/L (300)
at month 24, and 229 U/L (216) at month 36.
Fig. 3. Mean ± SE change from baseline to month 36 in GNEM-FAS total score (A), mobility score (B), upper extremity score (C), and
self-care score (D) in subjects who completed ≥200 and <200 meters at baseline. Subject numbers are shown above the x-axis. ∗P<0.05,
∗∗P<0.01, and ∗∗∗P<0.001 using the GEE model. GEE, generalized estimating equation; LS, least squares; SE, standard error.
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Fig. 5. Mean ± SE change from baseline to month 36 in the 6MWT
in all subjects (A) and in subjects who completed ≥200 and <200
meters at baseline (B). Subject numbers are shown above the x-
axis. *P<0.01 using the GEE model. 6MWT, six-minute walk
test; GEE, generalized estimating equation; LS, least squares; SE,
standard error.
Safety
No serious study procedure-specific events
occurred. Nine (9%) subjects experienced study
procedure-specific AEs, all of which were mild
(grade 1) in severity (Supplemental Table 4). Three
deaths occurred during the course of the study, all of
which were unrelated to participation in the study:
poisoning, colon cancer, and cardiac insufficiency.
There were no noteworthy changes throughout the
study in vital signs or standard safety laboratory
values.
DISCUSSION
To our knowledge, this in-clinic portion of the
GNEM-DMP was the first large multicenter, multi-
national, prospective natural history study using
validated measurements in GNE myopathy. Overall,
subjects with GNE myopathy showed a slow and pro-
gressive decline in clinical outcomes. Subjects with
GNE myopathy showed significant declines in upper
and lower muscle strength as early as 12 months, with
continued declines through months 24 and 36. After
month 24, there was a greater decline in the GNEM-
FAS total score in subjects who had greater disease
severity at baseline, as determined by the ability to
walk ≥200 meters in the 6MWT. Finally, because
there was no change over the study period, free SA
levels and creatine kinase levels were not meaningful
as markers of disease progression.
Although the HHD UE and LE composite scores
showed gradual declines throughout the study, the
rate of decline for each muscle group varies. Use
of the composite score to assess declines in muscle
strength overtime may be limited by muscle groups
that show a smaller rate of decline, such as the hip
adductors. Similarly, it may be difficult to detect
declines in muscle strength for subjects with vary-
ing disease severity based on genotype. Although
both subgroups demonstrated declines in UE and LE
composite scores overtime, Bulgarian subjects had
reduced muscle strength at baseline and post-baseline
assessments compared to non-Bulgarian subjects,
similar to what has been observed in a recent analy-
sis of the literature [13]. The change from baseline in
HHD UE scores was similar between Bulgarian and
non-Bulgarian subjects, whereas the decline in HHD
LE scores appeared greater in non-Bulgarian subjects
versus Bulgarian subjects.
Overall, subjects displayed significant declines by
month 24 in the GNEM-FAS, a validated tool that
aims to capture changes in signs and symptoms rel-
evant to GNE myopathy, including mobility, upper
extremity function, and self-care. A study validating
this tool reported that the clinically meaningful dif-
ference in the GNEM-FAS total score is a change
of approximately 3.6–8.0 units [10]. Subjects who
were able and unable to complete ≥200 meters in the
6MWT at baseline showed a decline greater than 3.6
units by month 24. Such findings support GNEM-
FAS as an appropriate tool to measure changes in
GNE myopathy. More research may help determine
the sensitivity of GNEM-FAS in subjects with greater
disease severity.
This study is not without limitations. The study,
originally planned to last up to 15 years, was discon-
tinued before all subjects reached later time points;
therefore, fewer subjects reached visits beyond 36
months and results beyond this timepoint were not
reported due to the limited interpretability with such
a small number of subjects. Still, data reported to
month 36 provide valuable insight into the natural
disease progression of GNE myopathy.
Our findings are consistent with the two studies
that have evaluated disease progression in smaller
groups of subjects with GNE myopathy, demonstrat-
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ing significant declines in muscle strength and less
significant declines in the 6MWT within roughly
one year [6, 7]. Although there are only two studies
examining the natural progression of GNE myopa-
thy, we can compare the results of subjects in this
natural history study who walked ≥200 meters at
baseline to those of 43 subjects with GNE myopathy
who received placebo in a phase 3 trial evaluating
an extended release formulation of aceneuramic acid
[13]. Subjects in the phase 3 study were required by
an inclusion criterion to be capable of walking ≥200
meters. Comparisons between these studies should
be made with caution, as 1) participants in the phase
3 trial were assessed with much more regularity and
could therefore have improved in clinical outcomes
with practice, and 2) the phase 3 trial was double-
blind, and therefore, placebo-treated participants did
not know if they were potentially benefiting from
active drug. Furthermore, the relatively small num-
ber of subjects who completed the 6MWT at baseline
and at later timepoints limited the to determine the
usefulness of the 6MWT as a measure of disease
progression.
In general, greater declines were observed after 11
months in the placebo-treated group of the phase 3
trial compared with changes observed over 12 months
in this natural history study for the HHD UE compos-
ite score, GNEM-FAS total score, and 6MWT, though
the reverse was true for the HHD LE composite score.
In the previous phase 3 study, a LS mean change of
–3.0 at roughly 11 months was observed in the HHD
UE composite score in 42 placebo—treated subjects;
this decline was greater than what was observed in
this natural history study at month 12 (–1.8). Sim-
ilarly, the decline in GNEM-FAS total score was
greater in placebo-treated subjects from the previous
phase 3 study at roughly 11 months (–4.05) compared
with subjects in this natural history study at month
12 (–1.3). Declines in the 6MWT were also greater
in placebo-treated subjects in the previous phase 3
trial at approximately 11 months (–6.8 m) compared
with declines in this natural history study (–1.5 and
3.2 at months 24 and 36, respectively). In contrast,
the decline in HHD LE composite score was greater
at month 12 (–3.2) in this natural history study com-
pared with the decline observed in subjects from the
earlier phase 3 trial after approximately 11 months
(–0.4).
Notably, a large subset of Bulgarian subjects, all
carrying the same homozygous GNE mutation, had
lower scores and further declines in all outcome mea-
sures compared with the non-Bulgarian subset of
subjects in our natural history study. This is in keep-
ing with previous estimates that 20% of the clinical
variability in GNE myopathy may be explained by the
primary mutation [13]. The GNE genotype should be
considered when designing clinical trials; treatment
groups in future trials may benefit from stratification
by genotype or by populations associated with highly
prevalent founder mutations.
Although declines in clinically relevant outcomes
typically occurred within a year in this natural history
study, in some situations, it may be informative for
trials investigating new therapeutic options for GNE
myopathy to evaluate clinical outcomes over a longer
durations (eg, 2 years). It may be beneficial to eval-
uate individual muscle groups in addition to UE and
LE composite scores, as well as clinical outcomes in
subjects with a specific mutation to determine disease
progression. The GNEM-FAS remains a valuable tool
to document disease progression in GNE myopathy.
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